Multivessel vs Single-Vessel Revascularization in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Multivessel Disease in the Drug-Eluting Stent Era
- Authors
- Lee, HJ[Lee, Hyun Jong]; Song, YB[Song, Young Bin]; Hahn, JY[Hahn, Joo-Yong]; Kim, SM[Kim, Sang Min]; Yang, JH[Yang, Ji Hyun]; Choi, JH[Choi, Joon Hyouk]; Choi, SH[Choi, Seung-Hyuk]; Choi, JH[Choi, Jin-Ho]; Lee, SH[Lee, Sang Hoon]; Gwon, HC[Gwon, Hyeon-Cheol]
- Issue Date
- Mar-2011
- Citation
- CLINICAL CARDIOLOGY, v.34, no.3, pp.160 - 165
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL CARDIOLOGY
- Volume
- 34
- Number
- 3
- Start Page
- 160
- End Page
- 165
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/70676
- DOI
- 10.1002/clc.20858
- ISSN
- 0160-9289
- Abstract
- Background: We sought to compare long-term outcomes for multivessel revascularization (MVR) vs single-vessel revascularization (SVR) with drug-eluting stents (DES) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and multivessel coronary artery disease (MVD). Hypothesis: In DES era, MVR would improve long-term clinical outcomes in patients with NSTE-ACS. Methods: We studied 179 patients undergoing MVR and 187 patients undergoing SVR for NSTE-ACS and MVD. Major adverse cardiac events (MACE) were defined as death, myocardial infarction, or any revascularization. Results: During follow-up (median 36 months), MACE occurred in 96 patients (26.2%); 35 (19.6%) in the MVR group and 61 (32.6%) in the SVR group (P = 0.003). In multivariate analysis, MVR was associated with a lower incidence of MACE (hazard ratio [HR]: 0.50, 95% confidence interval [CI]: 0.30-0.85) and revascularization (HR: 0.43, 95% CI: 0.24-0.78), but not of death (HR: 0.69, 95% CI: 0.25-1.93) and myocardial infarction (HR: 0.39, 95% CI: 0.11-1.47). The incidence of periprocedural renal dysfunction was not significantly different between patients undergoing MVR vs SVR (3.4% vs 1.6%, P = 0.33). Definite or probable stent thrombosis occurred at a similar rate (2.2% in the MVR group and 2.7% in the SVR group, P = 0.99). Conclusions: In patients with NSTE-ACS and MVD, MVR using drug-eluting stents may reduce MACE. Our findings should be confirmed by a prospective, randomized trial.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.